Novartis post hoc analysis shows high-dose Enerzair® Breezhaler® reduces asthma exacerbations versus medium-dose, complementing key pivotal IRIDIUM study findings
September 07, 2020 01:15 ET
|
Novartis International AG
High-dose, once-daily Enerzair® Breezhaler® [IND/GLY/MF] reduced asthma exacerbation rates by 21% (moderate or severe) and 31% (severe) versus medium-dose, over 52 weeks1 Once-daily Enerzair...
Novartis receives EC approval for Enerzair® Breezhaler®, including the first digital companion (sensor and app) that can be prescribed alongside a treatment for uncontrolled asthma in the EU
July 07, 2020 01:15 ET
|
Novartis International AG
European Commission approves once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) in the EU, the first-in-class LABA/LAMA/ICS fixed-dose combination for patients whose asthma is uncontrolled with...
Novartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options
June 29, 2020 02:45 ET
|
Novartis International AG
Basel, June 29, 2020 — Novartis Pharma K.K. (“Novartis Pharma”) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) simultaneously approved five new treatment options for...
Novartis Phase IIIb ARGON study meets primary endpoint in a comparison of Enerzair® Breezhaler® (QVM149) versus a free combination of two existing inhaled treatments in uncontrolled asthma
June 05, 2020 01:15 ET
|
Novartis International AG
Once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) met primary endpoint, demonstrating non-inferiority to a free combination of twice-daily Sal/Flu plus once-daily tiotropium (Tio), in improving...
Liquidia Appoints Tushar Shah, M.D., as Chief Medical Officer
May 18, 2020 07:15 ET
|
Liquidia Technologies, Inc.
RESEARCH TRIANGLE PARK, N.C., May 18, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and...
Liquidia Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 11, 2020 16:01 ET
|
Liquidia Technologies, Inc.
Received FDA Acceptance of LIQ861 NDA for ReviewReported Final Safety and Tolerability Results for LIQ861 Inspire TrialManagement to Host Webcast and Conference Call Today at 4:30p.m. ET ...
Novartis receives CHMP positive opinion for Enerzair® Breezhaler® (QVM149), a potential first-in-class inhaled LABA/LAMA/ICS combination for uncontrolled asthma
May 01, 2020 01:15 ET
|
Novartis International AG
CHMP positive opinion advances efforts to provide first-in-class LABA/LAMA/ICS combination for patients whose asthma is uncontrolled with LABA/ICS standard-of-care treatment in the EU. Digital...
Circadia Health Commits $3 million in Respiratory Monitors to Global COVID-19 Efforts
April 02, 2020 06:47 ET
|
Circadia Health
LONDON, April 02, 2020 (GLOBE NEWSWIRE) -- Circadia Health announces $3 million in medical devices and services towards COVID-19 relief efforts across the globe. The company has expedited the...
Humidity helps in the fight against COVID-19, virologists report
March 13, 2020 13:32 ET
|
Dan Hess Research
Washington, D.C., March 13, 2020 (GLOBE NEWSWIRE) -- What can the public do to defend against the COVID-19 coronavirus? One simple answer is to ramp up humidification at home and in the workplace,...
Novartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma
December 16, 2019 01:15 ET
|
Novartis International AG
Pooled analyses of LUSTER 1 and 2 did not support further development of Fevipiprant in asthma as a primary indication Fevipiprant was well tolerated with adverse events balanced across treatment...